Drug profile · INN
acarbose
ACARBOSE VIATRIS
acarbose (ACARBOSE VIATRIS) is a pancreatic alpha-amylase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — acarbose
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 1
- Data quality
- 0.84
Quick answer
acarbose (ACARBOSE VIATRIS) is a pancreatic alpha-amylase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Pancreatic alpha-amylase inhibitor
Primary target: Maltase-glucoamylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related patents
-
WO 2009026621
COMPOSÉ ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2677623
FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES
granted -
CA 2673418
COMPOSE ET COMPOSITION PHARMACEUTIQUES
granted -
CA 2673419
COMPOSITION PHARMACEUTIQUE
granted -
CA 2653382
COMPOSITION STABILISEE COMPRENANT DES INHIBITEURS DE L'ECA
granted -
CA 2628716
PROCESSUS DE REGULATION DE LA DIMENSION DE PARTICULE
granted
Frequently asked questions
What is acarbose?
acarbose (ACARBOSE VIATRIS) is a pancreatic alpha-amylase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acarbose?
ACARBOSE VIATRIS is a marketed brand name for acarbose. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acarbose?
acarbose has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.